PDK2 and colorectal carcinoma: Dichloroacetate (DCA), originally utilized to treat metabolic diseases as a metabolic regulator, was discovered to overcome chemoresistance in CRC through p53/miR‐149‐3p/pyruvate dehydrogenase kinase 2 (PDK2) glucose metabolic pathway.19